BR0306147A - Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição - Google Patents
Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composiçãoInfo
- Publication number
- BR0306147A BR0306147A BR0306147-7A BR0306147A BR0306147A BR 0306147 A BR0306147 A BR 0306147A BR 0306147 A BR0306147 A BR 0306147A BR 0306147 A BR0306147 A BR 0306147A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- serotonin
- activity
- compounds
- compound
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940076279 serotonin Drugs 0.000 title abstract 4
- 230000001270 agonistic effect Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000000966 norepinephrine reuptake Effects 0.000 title abstract 2
- 230000000697 serotonin reuptake Effects 0.000 title abstract 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 title 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001730 monoaminergic effect Effects 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020076344 EP1336406A1 (en) | 2002-02-14 | 2002-02-14 | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| PCT/EP2003/050015 WO2003068207A2 (en) | 2002-02-14 | 2003-02-11 | Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306147A true BR0306147A (pt) | 2004-10-19 |
Family
ID=27619173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306147-7A BR0306147A (pt) | 2002-02-14 | 2003-02-11 | Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050038015A1 (https=) |
| EP (2) | EP1336406A1 (https=) |
| JP (1) | JP2005517036A (https=) |
| KR (1) | KR20040081779A (https=) |
| CN (1) | CN1592614A (https=) |
| AU (1) | AU2003208714A1 (https=) |
| BR (1) | BR0306147A (https=) |
| CA (1) | CA2462688A1 (https=) |
| HR (1) | HRP20040276A2 (https=) |
| IL (1) | IL160942A0 (https=) |
| MX (1) | MXPA04004745A (https=) |
| NO (1) | NO20043833L (https=) |
| PL (1) | PL370632A1 (https=) |
| RU (1) | RU2004112546A (https=) |
| WO (1) | WO2003068207A2 (https=) |
| ZA (1) | ZA200404740B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU772189B2 (en) | 1999-08-23 | 2004-04-08 | Solvay Pharmaceuticals B.V. | New phenylpiperazines |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AR032711A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene |
| AR032712A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| CN1989968B (zh) | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| EP1595542A1 (en) * | 2004-03-26 | 2005-11-16 | Solvay Pharmaceuticals B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| WO2007019880A1 (en) * | 2005-08-18 | 2007-02-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome |
| WO2007065713A2 (en) * | 2005-12-08 | 2007-06-14 | Axxonis Pharma Gmbh | Use of 8-alpha-ergolines for the treatment of traumatic brain disorders |
| AU2008279572A1 (en) * | 2007-02-01 | 2009-01-29 | David Chau | Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
| JP2010534676A (ja) * | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療 |
| TW200936130A (en) * | 2008-02-26 | 2009-09-01 | Lundbeck & Co As H | Uses of indane compounds |
| WO2011082266A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| RU2664452C2 (ru) * | 2010-04-19 | 2018-08-17 | Нлифе Терапеутикс, С.Л. | Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви |
| CN111134894B (zh) * | 2020-01-17 | 2022-02-22 | 上海长海医院 | 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71590C2 (en) * | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| AU772189B2 (en) * | 1999-08-23 | 2004-04-08 | Solvay Pharmaceuticals B.V. | New phenylpiperazines |
-
2002
- 2002-02-14 EP EP20020076344 patent/EP1336406A1/en not_active Withdrawn
-
2003
- 2003-02-11 CN CNA038015544A patent/CN1592614A/zh active Pending
- 2003-02-11 WO PCT/EP2003/050015 patent/WO2003068207A2/en not_active Ceased
- 2003-02-11 MX MXPA04004745A patent/MXPA04004745A/es unknown
- 2003-02-11 BR BR0306147-7A patent/BR0306147A/pt not_active IP Right Cessation
- 2003-02-11 US US10/490,365 patent/US20050038015A1/en not_active Abandoned
- 2003-02-11 PL PL03370632A patent/PL370632A1/xx not_active Application Discontinuation
- 2003-02-11 EP EP03706621A patent/EP1476148A2/en not_active Withdrawn
- 2003-02-11 HR HR20040276A patent/HRP20040276A2/hr not_active Application Discontinuation
- 2003-02-11 AU AU2003208714A patent/AU2003208714A1/en not_active Abandoned
- 2003-02-11 KR KR10-2004-7012355A patent/KR20040081779A/ko not_active Ceased
- 2003-02-11 RU RU2004112546/15A patent/RU2004112546A/ru not_active Application Discontinuation
- 2003-02-11 IL IL16094203A patent/IL160942A0/xx unknown
- 2003-02-11 CA CA002462688A patent/CA2462688A1/en not_active Abandoned
- 2003-02-11 JP JP2003567389A patent/JP2005517036A/ja not_active Withdrawn
-
2004
- 2004-06-15 ZA ZA200404740A patent/ZA200404740B/en unknown
- 2004-09-13 NO NO20043833A patent/NO20043833L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1476148A2 (en) | 2004-11-17 |
| MXPA04004745A (es) | 2004-08-02 |
| HRP20040276A2 (en) | 2005-04-30 |
| IL160942A0 (en) | 2004-08-31 |
| CN1592614A (zh) | 2005-03-09 |
| WO2003068207A3 (en) | 2003-12-18 |
| AU2003208714A1 (en) | 2003-09-04 |
| US20050038015A1 (en) | 2005-02-17 |
| WO2003068207A2 (en) | 2003-08-21 |
| JP2005517036A (ja) | 2005-06-09 |
| PL370632A1 (en) | 2005-05-30 |
| RU2004112546A (ru) | 2005-03-27 |
| ZA200404740B (en) | 2005-08-23 |
| CA2462688A1 (en) | 2003-08-21 |
| NO20043833L (no) | 2004-09-13 |
| KR20040081779A (ko) | 2004-09-22 |
| EP1336406A1 (en) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0306147A (pt) | Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição | |
| PT1237553E (pt) | Combinacao de um inibidor de recaptacao da serotonina e de um antagonista, de um agonista inverso ou de um agonista parcial para o 5-ht2c | |
| WO2001001973A8 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
| BRPI0408863A (pt) | composto, composição farmacêutica, método para tratar doenças, e, uso de um composto. | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
| BRPI0514005A (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal, e, processo para a preparação de um composto | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| BRPI0606793A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica | |
| BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| MX344556B (es) | Agonista de subtipo de receptor 5-ht1a. | |
| BR0315346A (pt) | Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a | |
| ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| BRPI0515261A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo | |
| WO2004052858A3 (en) | Inhibitors of monoamine uptake | |
| BRPI0412268A (pt) | compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a | |
| BRPI0519921A2 (pt) | composto enanciopuro ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica,e, uso de composto quìmico ou de um sal farmaceuticamente aceitável do mesmo | |
| BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos | |
| BR0308911A (pt) | Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto | |
| WO2001023385A3 (en) | Novel tropane analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O E 6O ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010. |